KPV: A Research Overview

Introduction

KPV is a tripeptide corresponding to the carboxy-terminal three amino acids — lysine, proline, and valine — of α-melanocyte-stimulating hormone (α-MSH). In standard single-letter notation the sequence is rendered as the initialism KPV. As the smallest functional fragment of α-MSH demonstrating distinct anti-inflammatory activity in published research, KPV has attracted scientific interest as a probe for understanding the structural basis of peptide-mediated immunomodulation and the pharmacology of the melanocortin system. This article provides an educational reference overview of KPV's chemical identity, pharmacological classification, and regulatory context based on published primary literature.

Background

α-MSH is a 13-amino acid neuropeptide derived from the precursor protein proopiomelanocortin (POMC), processed in the pituitary and peripheral tissues. The full-length peptide carries an N-terminal acetyl group and a C-terminal amide, giving it the canonical structure Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. The final three residues — positions 11 through 13 — constitute the KPV sequence and have been the subject of independent investigation since researchers recognized that the C-terminal domain of α-MSH retains distinct biological activities that are pharmacologically separable from the functions concentrated in the central melanocortin pharmacophore [1].

Catania and Lipton published a foundational review in 1993 establishing that α-MSH modulates host defense reactions across multiple inflammatory models, and subsequent work from these and other groups progressively dissected which portions of the molecule accounted for which pharmacological activities [2]. The observation that the C-terminal fragment retained a distinct anti-inflammatory profile opened efforts to characterize KPV as a research entity in its own right — a line of inquiry that continues today.

Chemistry and Structure

KPV in its research form is typically encountered as the N-acetylated, C-terminally amidated tripeptide H-Lys-Pro-Val-NH₂, written Ac-KPV-NH₂. A mass spectrometric study of the acetylated amide form reported a calculated (M+H)⁺ of 384.26 [3]. The three constituent amino acids each contribute structurally relevant properties: lysine (K) provides a primary ε-amine group identified in structural modification studies as a site for chemical derivatization; proline (P) imposes conformational rigidity through its pyrrolidine ring, constraining the peptide backbone; and valine (V) contributes a branched hydrophobic terminus [3].

A conformational analysis of Ac-Lys-Pro-Val-NH₂ published in the Journal of Pharmacy and Pharmacology in 2001 characterized the solution geometry of the tripeptide, finding that the proline residue induces a bent backbone conformation that may contribute to the molecule's interaction profile with biological targets [4]. The structural resemblance of KPV's sequence to IL-1β(193-195) — the C-terminal tripeptide of interleukin-1 beta — has informed proposals that KPV and related peptides may interact with components of the IL-1 signaling axis, a research hypothesis explored further in the mechanism article in this series [5].

Pharmacological Classification

KPV occupies a distinctive position in melanocortin pharmacology. The melanocortin peptide family operates through five G protein-coupled receptor subtypes — MC1R through MC5R — with different peptide fragments engaging these receptors with varying specificity. While the full-length α-MSH peptide engages MC1R and MC3R with the highest functional relevance in immunomodulatory contexts, published research has characterized KPV's pharmacological profile as distinct from direct melanocortin receptor agonism. Luger and Brzoska noted in a 2007 review that KPV "seems not to bind to MC-1R and fails to increase cyclic adenosine monophosphate (cAMP) levels," indicating the tripeptide operates through a complementary mechanism [5]. This receptor-independent pharmacology distinguishes KPV from other melanocortin-derived peptides in the same research cluster, such as MT-II and MT-2, which retain high-affinity melanocortin receptor engagement.

This receptor-independent profile positions KPV as a research tool for interrogating non-classical immunomodulatory pathways downstream of the melanocortin system. Published research has associated KPV's anti-inflammatory activity primarily with interference in NF-κB nuclear translocation, as detailed in the mechanism article in this series [6]. The peptide has also been reported to interact with components of the IL-1β signaling pathway [5]. Together, these findings have framed KPV as a probe for understanding how small fragments of neuropeptides can retain and redirect the signaling profiles of their parent molecules.

Regulatory Status

KPV is not approved by the United States Food and Drug Administration for any therapeutic indication. No IND filing or NDA for KPV as a drug substance is referenced in publicly available FDA databases. KPV is therefore classified as a research compound; published literature on the molecule derives from preclinical and in vitro research settings. The broader melanocortin peptide class has produced approved pharmaceutical products for other pharmacological targets — bremelanotide (Vyleesi), an MC4R agonist, received FDA approval in 2019 — demonstrating the translational potential of the melanocortin research program of which KPV is a part.

Discovery History

The anti-inflammatory properties of α-MSH were reported as early as 1986, when Cannon and colleagues published findings that α-MSH inhibited immunostimulatory and inflammatory actions of interleukin-1 in vitro and in vivo [7]. The systematic dissection of which regions of the α-MSH sequence carried which functional activities advanced through the 1990s. Lipton and colleagues published work in 1994 describing the anti-inflammatory effects of the neuropeptide across multiple inflammation models, and Lipton and Catania's 1997 review in Immunology Today formalized α-MSH's classification as a neuroimmunomodulator [8, 9].

The specific characterization of KPV as a pharmacologically distinct fragment was crystallized in a 2003 paper by Getting, Schiöth, and Perretti, which dissected the contributions of the core pharmacophore versus the C-terminal KPV sequence in a peritonitis model [1]. That study provided foundational evidence that the anti-inflammatory profile of the C-terminal fragment was mechanistically separable from canonical melanocortin receptor agonism, establishing KPV as a subject of independent research investigation. Subsequent work through the 2010s deepened mechanistic understanding and explored novel delivery approaches, as documented in the research and history articles in this series. Researchers requiring verified material for this work can review synthesis and analytical standards in the KPV sourcing and quality article, or access research-grade KPV from SpartaLabs.

References

1. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. PMID: 12750433. DOI: 10.1124/jpet.103.051623

2. Catania A, Lipton JM. Alpha-melanocyte stimulating hormone in the modulation of host reactions. Endocr Rev. 1993;14(5):564-576. PMID: 8262006. DOI: 10.1210/edrv-14-5-564

3. Songok AC, Panta P, Doerrler WT, Macnaughtan MA, Taylor CM. Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue. PLoS One. 2018;13(6):e0199686. PMID: 29953505. DOI: 10.1371/journal.pone.0199686

4. Chavatte P, Yous S, Lesieur D, Hénichart JP. Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH2, COOH-terminal sequence of alpha-MSH. J Pharm Pharmacol. 2001;53(7):949-953. PMID: 11480545. DOI: 10.1211/0022357011776360

5. Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66(Suppl 3):iii52-iii55. PMID: 17934097. DOI: 10.1136/ard.2007.079780

6. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805

7. Cannon JG, Tatro JB, Reichlin S, Dinarello CA. Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. J Immunol. 1986;137(7):2232-2236. PMID: 3489761

8. Lipton JM, Ceriani G, Macaluso A, McCoy D, Carnes K, Biltz J, Catania A. Antiinflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation. Ann N Y Acad Sci. 1994;741:137-148. PMID: 7825801. DOI: 10.1111/j.1749-6632.1994.tb39654.x

9. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today. 1997;18(3):140-145. PMID: 9078687. DOI: 10.1016/s0167-5699(97)01009-8